首页> 外文期刊>Endocrine journal >Clinical Characteristics of Primary Thyroid Lymphoma in Koreans
【24h】

Clinical Characteristics of Primary Thyroid Lymphoma in Koreans

机译:韩国原发性甲状腺淋巴瘤的临床特征

获取原文
获取原文并翻译 | 示例
       

摘要

Primary thyroid lymphoma is a very rare tumor and its prevalence is approximately 0.1% of all thyroid cancers in Korea. Its clinical experience is limited and not familiar to physicians. Therefore, we performed this study to investigate the clinical characteristics of primary thyroid lymphoma in Koreans. We retrospectively analyzed the medical records of the 44 patients with primary thyroid lymphoma from 1991 to 2006 at four major referral hospitals in Korea. Out of 44 patients, eight patients were male and 36 patients were female and their average age was 57 years. Fifty-six percent of patients had underlying Hashimoto's thyroiditis. All but two patients had non-Hodgkin's lymphoma with B cell origin, and eighty percent of patients presented with stage IE or IIE. Twenty-one of 44 patients (48%) had diffuse large B cell lymphoma (DLBCL) and 17 (39%) had MALT lymphoma. Malignancies originating from lymphoid cells were suspected in 10 of eighteen patients with DLBCL (56%) by using fine-needle aspiration cytology (FNAC), and no difference was noted compared with MALT lymphoma (64%). Compared with DLBCL, the patients with MALT lymphoma were more frequently presented with stage I disease (DLBCL vs. MALT lymphoma: 32% vs. 65%, P=0.04). Moreover, in contrast to DLBCL, most of the patients with MALT lymphoma achieved complete response with treatments (DLBCL vs. MALT lymphoma: 53% vs. 94%, P<0.01). Because of the low diagnostic accuracy of FNAC, thyroid biopsy should be considered for the diagnosis of thyroid lymphomas in suspicious cases. The patients with MALT lymphoma were more frequently presented with early stage diseases and this might lead to the favorable outcome to treatments than those with DLBCL.
机译:原发性甲状腺淋巴瘤是一种非常罕见的肿瘤,在韩国,其患病率约为所有甲状腺癌的0.1%。它的临床经验是有限的,医师们并不熟悉。因此,我们进行了这项研究,以调查韩国人原发性甲状腺淋巴瘤的临床特征。我们回顾性分析了1991年至2006年韩国四家主要转诊医院的44例原发性甲状腺淋巴瘤患者的病历。在44例患者中,男性8例,女性36例,平均年龄为57岁。 56%的患者患有潜在的桥本甲状腺炎。除两名患者外,所有患者均患有非霍奇金淋巴瘤,起源于B细胞,并且80%的患者为IE或IIE期。 44例患者中有21例(48%)患有弥漫性大B细胞淋巴瘤(DLBCL),17例(39%)患有MALT淋巴瘤。通过细针穿刺细胞学检查(FNAC),在18例DLBCL患者中,有10例怀疑来自淋巴样细胞的恶性肿瘤(56%),与MALT淋巴瘤(64%)相比没有发现差异。与DLBCL相比,MALT淋巴瘤患者更易出现I期疾病(DLBCL vs. MALT淋巴瘤:32%vs. 65%,P = 0.04)。此外,与DLBCL相比,大多数MALT淋巴瘤患者通过治疗获得了完全缓解(DLBCL vs. MALT淋巴瘤:53%vs. 94%,P <0.01)。由于FNAC的诊断准确性较低,在可疑病例中应考虑进行甲状腺活检来诊断甲状腺淋巴瘤。 MALT淋巴瘤患者更容易出现早期疾病,与DLBCL相比,这可能导致治疗效果更好。

著录项

  • 来源
    《Endocrine journal》 |2009年第3期|399-405|共7页
  • 作者单位

    Division of Endocrinology and Metabolism, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea;

    Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea;

    Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea;

    Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea;

    Department of Internal Medicine, Korea Cancer Center Hospital, Seoul, Korea;

    Division of Endocrinology, Department of Internal Medicine, Chungnam National University School of Medicine, Daejeon, Korea;

    Division of Endocrinology, Department of Internal Medicine, Eulji University School of Medicine, Daejeon, Korea;

    Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea;

    Division of Endocrinology and Metabolism, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea;

  • 收录信息 美国《科学引文索引》(SCI);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

    primary lymphoma of thyroid; diffuse large B cell lymphoma; MALT lymphoma; fine needle aspiration cytology;

    机译:甲状腺原发性淋巴瘤;弥漫性大B细胞淋巴瘤MALT淋巴瘤;细针穿刺细胞学;
  • 入库时间 2022-08-18 01:33:46

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号